Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents: 5 years of experience.

Author: CahnPedro, De AquinoMaria Zilda, Della NegraMarinella, JelaskaAnte, MiklJaromir, RobinsonPatrick A, SalazarJuan C

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the long-term safety, efficacy, and tolerability of ritonavir-boosted tipranavir in HIV-1-infected pediatric patients. Pediatric patients who began treatment at younger ages and were stable on a ritonavir-boosted tipranavir-based regimen at week 48 generally continued to demonstrate good safety, tolerability, and virologic efficacy profiles up to 292 weeks of treatment.
Paper Details　
Original Abstract of the Article :
BACKGROUND: To evaluate the long-term (up to week 292) safety, efficacy and tolerability of ritonavir-boosted tipranavir in HIV-1-infected pediatric patients. Long-term follow up of patients enrolled in the randomized, open-label pediatric trial (1182.14/PACTG1051). METHODS: HIV-1-infected pediatri...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/INF.0000000000000038

データ提供：米国国立医学図書館（NLM）

Tipranavir/Ritonavir for HIV-1 Infection in Children and Adolescents: A Long-Term Evaluation

Treating HIV-1 infection in children and adolescents poses unique challenges due to their developing immune systems. This study investigates the long-term safety, efficacy, and tolerability of a ritonavir-boosted tipranavir-based regimen in HIV-1-infected pediatric patients. The researchers analyzed data from a long-term follow-up of patients enrolled in a randomized, open-label pediatric trial to assess the effectiveness of this treatment approach over an extended period.

Long-Term Efficacy and Safety: A Promising Outcome

This study provides encouraging evidence that a ritonavir-boosted tipranavir-based regimen demonstrates good long-term safety, tolerability, and virologic efficacy in pediatric patients who begin treatment at an early age and are stable on the regimen. It’s like finding a safe and reliable path through the complex desert of HIV-1 infection, offering a glimmer of hope for children and adolescents facing this challenging condition. The study highlights the importance of early intervention and long-term follow-up in effectively managing HIV-1 infection in pediatric patients.

Navigating the Shifting Sands of HIV-1 Treatment

The study acknowledges that treatment outcomes may vary based on the age at which treatment is initiated, highlighting the need for individualized treatment plans tailored to the specific needs of each patient. It’s like navigating a dynamic desert landscape, where flexibility and adaptability are essential to finding the right path to success. The study emphasizes the importance of continued research and ongoing monitoring to optimize treatment strategies and improve outcomes for children and adolescents with HIV-1 infection.

Dr.Camel's Conclusion

This research provides valuable insights into the long-term safety, efficacy, and tolerability of a ritonavir-boosted tipranavir-based regimen in HIV-1-infected pediatric patients. The findings suggest that this treatment approach holds promise for effectively managing HIV-1 infection in this vulnerable population. It's like discovering a hidden oasis in the desert of HIV-1 treatment, offering a source of relief and hope for children and adolescents battling this challenging condition.
Date :
  1. Date Completed 2015-03-30
  2. Date Revised 2020-12-09
Further Info :

Pubmed ID

23995585

DOI: Digital Object Identifier

10.1097/INF.0000000000000038

Related Literature

Article Analysis
・Effects of tipranavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.